Latest filing published 03 Feb 2023 for Poseida Therapeutics, Inc., €76k.
Filing timeline
BuySaleInsider track record
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Eric Ostertag: trading record in brief
This profile gathers the share dealings of Eric Ostertag in Poseida Therapeutics, Inc., where the filings describe the role as chief executive. We count 58 filings; the first trade dates from 14 July 2020 and the latest from 1 February 2023.
The open-market side counts 1 purchase for €490k alongside 44 sales for €6.7M. Netting one side against the other leaves €6.2M of net selling. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 2 share grants and 7 option exercises.
The latest filing, published on 3 February 2023, reports a share grant of €76k in Poseida Therapeutics, Inc. The last purchase on record was published on 10 August 2022, which is 1,552 days ago. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Eric Ostertag
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 11,776 shares@ US$7.002.5% of flowCommon StockSEC:0001209191-23-006828:0
- 142,857 shares@ US$3.5016.5% of flowCommon StockSEC:0001209191-22-045296:0Canonical exit: 6 Nov 2022 (T+90)
- 160,696 shares@ US$3.68919.6% of flowCommon StockSEC:0001209191-22-044562:0
- 48,902 shares0Common StockSEC:0001209191-22-006170:1
- 89,500 shares0Common StockSEC:0001209191-22-006170:2
- 93,955 shares0Common StockSEC:0001209191-22-006170:0
- 1,000 shares@ US$9.150.3% of flowCommon StockSEC:0001209191-21-066229:0
- 9,051 shares@ US$7.090.6% of flowCommon StockSEC:0001209191-21-063934:1
- 9,873 shares@ US$7.092.0% of flowCommon StockSEC:0001209191-21-063934:0
- 18,525 shares@ US$9.154.9% of flowCommon StockSEC:0001209191-21-060403:0
- 9,579 shares@ US$7.020.7% of flowCommon StockSEC:0001209191-21-059651:1
- 10,450 shares@ US$7.022.1% of flowCommon StockSEC:0001209191-21-059651:0
- 20,000 shares@ US$8.0014.6% of flowCommon StockSEC:0001209191-21-057289:0
- 18,524 shares@ US$9.151.7% of flowCommon StockSEC:0001209191-21-056246:1
- 20,000 shares@ US$8.141.6% of flowCommon StockSEC:0001209191-21-056246:2
- 2,757 shares@ US$1.1730.1% of flowCommon StockSEC:0001209191-21-056246:0
- 31,963 shares@ US$8.342.6% of flowCommon StockSEC:0001209191-21-054797:1
- 24,463 shares@ US$8.462.0% of flowCommon StockSEC:0001209191-21-054797:2
- 29,299 shares@ US$8.342.4% of flowCommon StockSEC:0001209191-21-054797:3
- 26,686 shares@ US$8.466.4% of flowCommon StockSEC:0001209191-21-054797:0
- 111,149 shares@ US$9.1528.9% of flowCommon StockSEC:0001209191-21-050697:0
- 10,401 shares@ US$7.990.8% of flowCommon StockSEC:0001209191-21-049673:1
- 6,570 shares@ US$8.130.5% of flowCommon StockSEC:0001209191-21-049673:2
- 9,535 shares@ US$7.990.7% of flowCommon StockSEC:0001209191-21-049673:3
- 7,167 shares@ US$8.131.6% of flowCommon StockSEC:0001209191-21-049673:0
25 of 58 declarations
